Conversely, the BOREAS and NOTUS studies, which investigated anti-IL-4/IL-13 therapies, enrolled COPD patients with a blood eosinophil count of 300 cells per microliter or higher to receive subcutaneous Dupilumab or a placebo biweekly [91,92]. This evidence concerns the gene IL4 and chronic obstructive pulmonary disease.